Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
Dow
AstraZeneca
McKinsey

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Candesartan Cilexetil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108706 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status Takeda Phase 4 2004-12-01 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00108706 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status City Hospitals Sunderland NHS Foundation Trust Phase 4 2004-12-01 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00125463 Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients Unknown status The Japanese Society of Hypertension Phase 3 2001-09-01 The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil– Blopress®) and a calcium channel blocker (amlodipine besilate– Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed Japan Heart Foundation Phase 4 2005-10-01 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed The 4C trial bureau Phase 4 2005-10-01 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed Kumamoto University Phase 4 2005-10-01 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
NCT00150631 Danish Hypertension Prevention Project - DHYPP Unknown status AstraZeneca Phase 3 2000-11-01 The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Candesartan Cilexetil

Condition Name

Condition Name for Candesartan Cilexetil
Intervention Trials
Hypertension 25
Essential Hypertension 5
Healthy 3
Congestive Heart Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Candesartan Cilexetil
Intervention Trials
Hypertension 26
Heart Failure 4
Retinal Diseases 3
Diabetic Retinopathy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Candesartan Cilexetil

Trials by Country

Trials by Country for Candesartan Cilexetil
Location Trials
United States 100
Japan 30
Korea, Republic of 20
United Kingdom 13
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Candesartan Cilexetil
Location Trials
California 6
Ohio 5
North Carolina 5
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Candesartan Cilexetil

Clinical Trial Phase

Clinical Trial Phase for Candesartan Cilexetil
Clinical Trial Phase Trials
Phase 4 10
Phase 3 23
Phase 2 5
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Candesartan Cilexetil
Clinical Trial Phase Trials
Completed 37
Unknown status 9
Not yet recruiting 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Candesartan Cilexetil

Sponsor Name

Sponsor Name for Candesartan Cilexetil
Sponsor Trials
AstraZeneca 19
Takeda 13
CJ HealthCare Corporation 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Candesartan Cilexetil
Sponsor Trials
Industry 54
Other 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Johnson and Johnson
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.